Compare JFIN & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | HELP |
|---|---|---|
| Founded | 2011 | N/A |
| Country | China | Canada |
| Employees | N/A | 50 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.1M | 279.9M |
| IPO Year | 2018 | N/A |
| Metric | JFIN | HELP |
|---|---|---|
| Price | $4.89 | $5.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 40.7K | ★ 1.5M |
| Earning Date | 06-03-2026 | 07-01-2026 |
| Dividend Yield | ★ 17.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.70 | $4.29 |
| 52 Week High | $18.70 | $8.55 |
| Indicator | JFIN | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 51.78 |
| Support Level | $3.70 | $4.55 |
| Resistance Level | $5.00 | $6.26 |
| Average True Range (ATR) | 0.21 | 0.48 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 83.19 | 44.02 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.